

# Competitor Analysis: Proteasome Inhibitors

<https://marketpublishers.com/r/CA501D66415EN.html>

Date: November 2009

Pages: 14

Price: US\$ 120.00 (Single User License)

ID: CA501D66415EN

## Abstracts

### Product description

The present Competitive Intelligence Report about Proteasome Inhibitors provides a competitor evaluation in the field of novel small molecules and peptides targeting the proteasome for treatment of cancer as of November 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The proteasome is involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. Due to the importance of the proteasome in cellular functions, inhibition or activation of the proteasome could become a useful therapeutic strategy for a variety of diseases.

Many proteasome inhibitors have been identified and can be classified into two groups according to their source: chemically synthesized small molecules and compounds derived from natural products. A successful example of development of a proteasome inhibitor as a clinically useful drug is the peptide boronate, PS341 (Bortezomib). The drug was approved for the treatment of multiple myeloma. In contrast to proteasome inhibitors, small molecules that can activate or enhance proteasome activity are rare and are not well studied. Despite the commercial success of Velcade, the pipeline of novel proteasome inhibitors is not overcrowded which might indicate the difficulties in identifying new clinical candidates, but also offers a competitive advantage.

The report includes a compilation of current active projects in research and development of molecules targeting the proteasome. In addition, the report lists company-specific R&D pipelines of proteasome targeting small molecules and peptides. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

## **Index**

Velcade Pipeline

Proteasome Inhibitors

Corporate Proteasome Inhibitor R&D Pipelines

About La Merie

## **About Competitor Analysis Series**

The Competitor Analysis Series delivers **NO-FRILLS** , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies **at low prices**. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to **R&D Pipeline News**. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations.

## I would like to order

Product name: Competitor Analysis: Proteasome Inhibitors

Product link: <https://marketpublishers.com/r/CA501D66415EN.html>

Price: US\$ 120.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA501D66415EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970